ALZN — Alzamend Neuro Cashflow Statement
0.000.00%
Last trade - 00:00- $4.43m
- $1.07m
Annual cashflow statement for Alzamend Neuro, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.41 | -5.05 | -12.4 | -14.9 | -9.95 |
| Depreciation | |||||
| Non-Cash Items | 2.36 | 2.49 | 4.42 | 3.58 | 0.956 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.299 | -0.152 | 1.33 | 2.35 | 0.671 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -2.35 | -2.71 | -6.61 | -8.92 | -8.27 |
| Capital Expenditures | — | — | -0.106 | 0 | -0.147 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.105 | 0.101 | 0 | — | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.105 | 0.101 | -0.106 | 0 | -0.147 |
| Financing Cash Flow Items | 0 | 1.95 | -0.059 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.29 | 4.45 | 18.9 | 0 | 3.65 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.048 | 1.84 | 12.1 | -8.92 | -4.76 |